GLPwatch
Impacts of tirzepatide on older patients with diminished β-cell function and dementia.
Geriatr Gerontol Int · 2025
Last updated 2026-05-28In older patients with diabetes and reduced β-cell function, tirzepatide improved blood sugar control after meals, even when these cells were not working well. However, it did not replace the need for basal insulin in these cases and required careful monitoring for muscle loss.
AI summary of the abstract below.
| Journal | Geriatr Gerontol Int, 2025 |
|---|---|
| Citations | 3 |
| Molecules | tirzepatide |
| Conditions studied | Type 2 Diabetes, Alzheimers |
Abstract
Tirzepatide could control postprandial hyperglycemia even in cases with diminished β-cell function. This finding gives new insight into the treatment of older patients with diabetes. However, tilzepatide does not replace basal insulin in cases with diminished β-cell function and requires careful observation for sarcopenia.
Verbatim abstract via PubMed 40001315 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.